89bio (ETNB) provided a corporate update and business outlook for 2025. Completed enrollment in Phase 3 ENTRUST trial in patients with severe hypertriglyceridemia; topline 26-week data expected in the second half of 2025. The Phase 3 ENLIGHTEN program in patients with non-cirrhotic and compensated cirrhotic metabolic dysfunction-associated steatohepatitis continues to enroll patients across both trials. Cash, cash equivalents, and marketable securities totaled approximately $440 million as of December 31, 2024
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ETNB:
Questions or Comments about the article? Write to editor@tipranks.com